Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Flanigan

Showing results (21-30 of 358) with videos related to

Pageof 36
Sort By:
Infectious Disease Clinics of North America|January 6, 2001
Antiretroviral therapy in the year 2000K T Tashima, T P Flanigan
Medicine and Health, Rhode Island|November 14, 1997
Human immunodeficiency virus infection and sexually transmitted diseasesS C Uvin, T P Flanigan
Surgery|October 1, 1986
Antibiotic binding to polytetrafluoroethylene via glucosaminoglycan-keratin luminal coatingK R Sobinsky, D P Flanigan
Medicine and Health, Rhode Island|April 22, 2003
Point of view: the rapid spread of HIV among minority communities in the United States: a call to actionEmma M Simmons, Timothy P Flanigan
Medicine and Health, Rhode Island|March 24, 2000
HIV, infectious diseases, and competitive athleticsA A Feller, T P Flanigan
Surgery Annual|January 1, 1982
Venous insufficiency of the lower extremities: new methods of diagnosis and therapyD P Flanigan, L R Williams
The Journal of Infectious Diseases|April 14, 2017
Effective HIV Prevention Interventions and the Need for Rapid Mobilization to Address HIV Outbreaks Among At-Risk PopulationsPhilip A Chan, Timothy P Flanigan
Pediatrics in Review|December 1, 1994
GastroenteritisR S Northrup, T P Flanigan
The Journal of Infectious Diseases|April 1, 1992
Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell lineR J Marshall, T P Flanigan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 3, 2006
The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficultTimothy P Flanigan, Jennifer A Mitty
Pageof 36

Showing results (21-30 of 358) with videos related to

Sort By:
Pageof 36
Infectious Disease Clinics of North America|January 6, 2001
Antiretroviral therapy in the year 2000K T Tashima, T P Flanigan
Medicine and Health, Rhode Island|November 14, 1997
Human immunodeficiency virus infection and sexually transmitted diseasesS C Uvin, T P Flanigan
Surgery|October 1, 1986
Antibiotic binding to polytetrafluoroethylene via glucosaminoglycan-keratin luminal coatingK R Sobinsky, D P Flanigan
Medicine and Health, Rhode Island|April 22, 2003
Point of view: the rapid spread of HIV among minority communities in the United States: a call to actionEmma M Simmons, Timothy P Flanigan
Medicine and Health, Rhode Island|March 24, 2000
HIV, infectious diseases, and competitive athleticsA A Feller, T P Flanigan
Surgery Annual|January 1, 1982
Venous insufficiency of the lower extremities: new methods of diagnosis and therapyD P Flanigan, L R Williams
The Journal of Infectious Diseases|April 14, 2017
Effective HIV Prevention Interventions and the Need for Rapid Mobilization to Address HIV Outbreaks Among At-Risk PopulationsPhilip A Chan, Timothy P Flanigan
Pediatrics in Review|December 1, 1994
GastroenteritisR S Northrup, T P Flanigan
The Journal of Infectious Diseases|April 1, 1992
Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell lineR J Marshall, T P Flanigan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 3, 2006
The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficultTimothy P Flanigan, Jennifer A Mitty
Pageof 36